NEW YORK (GenomeWeb News) – Rosetta Genomics reported after the close of the market on Monday a sharp increase in revenues for the for the six-month period ended June 30, as the company expanded access to its suite of microRNA-based cancer diagnostics.

During the first half of 2013, Rosetta's revenues rose to $193,000 from $51,000 in the same period the year before.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: caution urged in use of gene drives, and more.

NIH's Sally Rockey examines the tapped and untapped potential of the NIH peer reviewer pool.

PLOS Biology has asked researchers how they envision the future of genetics and genomics.

Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."

Sep
10
Sponsored by
Qiagen

In this online seminar, Jo Vandesompele of the Center for Medical Genetics at Ghent University will discuss methods for improving the analysis of microRNA expression from a range of samples.